Regenerative Medical Technology Group Inc. (RMTG) intrinsic value & 10-year financials
Regenerative Medical Technology Group Inc. (RMTG) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 90.6% a year to $5.1M, with an average return on invested capital of 48.6%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.04
- Market cap
- $475.1K
- Revenue (FY2025)
- $5.1M
- Revenue growth (10-yr CAGR)
- 90.6%
- ROIC (10-yr avg)
- 48.6%
- Free cash flow (FY2025)
- -$1.3M
RMTG 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $5.1M | -$7.8M | -$0.62 | -$1.3M | -17.0% | 2.3% |
| FY2024 | $4.1M | -$5.6M | -$0.44 | $635.3K | 2.0% | -0.2% |
| FY2023 | $2.4M | -$9.8M | -$0.79 | -$804.8K | -29.7% | 4.3% |
| FY2022 | $1.5M | -$5.5M | -$0.45 | -$1.3M | — | 40.4% |
| FY2021 | $475.3K | -$12.9M | -$1.12 | — | — | 195.7% |
| FY2020 | $55.1K | -$5.9M | — | -$422.7K | — | 85.7% |
| FY2019 | $30.1K | -$2.5M | — | -$462.3K | — | 42.2% |
| FY2018 | $50.1K | -$2.1M | — | -$248.6K | — | 58.0% |
| FY2017 | $29.2K | -$377.0K | — | — | — | 9.3% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Regenerative Medical Technology Group Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Regenerative Medical Technology Group Inc. has earned high returns on invested capital, averaging 27.1% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Regenerative Medical Technology Group Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Regenerative Medical Technology Group Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-20.59 per share.